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Background: This study aimed to evaluate the strength of anti‑Mullerian hormone (AMH) and follicle stimulating hormone (FSH)
in reflecting the antral follicle count (AFC) in infertile females. Materials and Methods: This cross‑sectional study was conducted
on 160 females, visiting infertility clinic for assisted reproduction. Serum samples collected on the 3rd day of the cycle were assayed
for FSH, luteinizing hormone, and AMH while AFC was assessed via transvaginal ultrasound. The study cohort was segregated into
three groups based on AFC. Results: Chronological age and FSH was significantly high in females with very low AFC (P < 0.01 and
0.009, respectively), yet they failed to discriminate patients with normal and higher follicle count (P = 0.65 and 0.84). Conversely,
AMH reported highly significant difference between very low AFC and with those having either normal AFC (P = 0.002) or higher
AFC (P = 0.001). Moreover, a significant difference in AMH was observed between normal and higher AFC group (P = 0.04).
Conclusion: Compared to female’s age and FSH, AMH is superior in clustering study cohort on the bases of antral follicular pool,
especially in setups with nonavailability of technological expertise to assess AFC. Incorporation of AMH along with other biomarkers
improves estimation of baseline ovarian reserve, required to standardize dose for optimum response; avoiding the risk of failure to
retrieve oocyte or inappropriate stimulation leading to ovarian hyperstimulation syndrome. Further prospective studies are required
to ascertain its role in predicting the outcomes of ART in such patients.
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follicle count (AFC), and ovarian volume.[2,3] These have
been summarized in Table 1.

INTRODUCTION
Assessment of the status of an ovarian function is
essential to evaluate and plan infertility interventions.
In recent times, estimation of ovarian reserve (OR) is
the most commonly used criteria to reflect the quality
and quantity of oocytes, in turn imitating the fertility
potential of a female.[1] With advancing age, a drop in
the extent of OR proportionately reflects decline in a
female’s reproductive capabilities. Hence, its estimation
provides an approximation of fertile years left for a
woman. Several markers are used to reflect OR in
infertility clinics that include patient’s age, serum follicle
stimulating hormone (FSH), luteinizing hormone (LH),
anti‑Mullerian hormone (AMH), estradiol levels, antral
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AFC is considered as a gold standard for measurement
of OR and is considered necessary before planning
assisted reproduction support. [4] It is suggested
that an optimum response to infertility assistance is
reflected as a retrieval of at least 5 oocytes on ovarian
stimulation.[5] Furthermore, an exaggerated AFC (>19)
is linked to potential complications such as ovarian
hyper stimulation syndrome (OHSS), [3] rendering
its evaluation as a better tool for optimization
of protocol that may reduce the chances of cycle
cancellation. However, it has its own drawbacks
such as prerequisite of a skilled operator and latest
machinery that reliably assess the count.[6] In addition,
its inability to reveal the quality of healthy oocytes
This is an open access article distributed under the terms of the
Creative Commons Attribution‑NonCommercial‑ShareAlike 3.0
License, which allows others to remix, tweak, and build upon
the work non‑commercially, as long as the author is credited
and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com

Address for correspondence: Dr. Zehra Jamil, Department of Biological and Biomedical Sciences, Faculty of Health Sciences, Medical College,
Aga Khan University, Stadium Road, P.O. Box 3500, Karachi‑74800, Pakistan. E‑mail: zehra.jamil@aku.edu
Received: 26‑04‑2016; Revised: 22‑06‑2016; Accepted: 13-07-2016

1

© 2016 Journal of Research in Medical Sciences | Published by Wolters Kluwer - Medknow

| 2016 |

[Downloaded free from http://www.jmsjournal.net on Monday, September 10, 2018, IP: 221.132.113.70]

Jamil, et al.: AMH as a better ovulation indicator

Table 1: Ovarian reserve tests and markers adapted
from Jirge, 2011
Tests
Biological
Biochemical

Biophysical

Histological

Ovarian reserve marker
Chronological age
FSH
LH
FSH: LH ratio
Inhibin B
Estradiol
AMH
CCCT
GAST
EFORT
AFC
Ovarian volume
Ovarian blood flow
Ovarian biopsy

CCCT=Clomiphene citrate challenge test; GAST=Gonadotropin‑releasing hormone
agonist stimulation test; EFORT=Exogenous FSH ovarian reserve test; FSH=Follicle
stimulating hormone; LH=Luteinizing hormone; AMH=Anti Mullerian hormone;
AFC=Antral follicle count

results in counting even those follicles that may not act
in response to treatment.[7]
At present, in setups that lack ultrasonography facilities
for the assessment of AFC, serum FSH is widely used
along with patient’s age; based on these markers, patients
are either advised to farther wait for natural conception
or offered infertility treatment. Various studies imply
chronological age as a weak predictor of fertility as even
young patients at the times report reduced OR.[8] In regards
to FSH, it shows high degree of variability as factors such
as exogenous administration of FSH in the form of oral
contraceptive pills (OCP) can alter the results obtained.[9]
Nowadays, AMH is being preferred over other indicators
as its levels are independent of menstrual cycle phases and
is fairly easier to estimate through blood sampling.[9]
In this study, we aimed to compare the true accuracy of
AMH and FSH in correlating with the number of AFC
in infertile population. For this purpose, we divided the
cohort into three subgroups based on AFC count; those
with <5 follicles (Group A), between 5 and 19 (Group B),
and greater than 19 follicles (Group C). We evaluated the
strength of AMH and FSH in characterizing the population
into sub‑groups and witnessed AMH as a superior predictor
in distinguishing among them.

MATERIALS AND METHODS
This cross‑sectional study was conducted by means
of the data collected from 160 infertile females, aged
20–43 years who visited Australian Concept Infertility
Medical Center (ACIMC) during June 2014 to March 2015.
Institutional review board of ACIMC granted the exception
| 2016 |

of Ethical Review consent as this retrospective study could
not affect the clinical decision made for infertility treatment.
The anonymity of the records was carried out in view of
keeping patient confidentiality intact. Besides age, the
inclusion criteria also required that participants had intact
female reproductive organs and no history of prior ovarian
procedures or endocrine dysfunction. Women who had
previously received ovarian stimulation treatment or OCP
were excluded from the study.
The serum samples were obtained over days 3 of the
menstrual cycle from all participants for baseline AMH,
FSH, and LH measurements before the commencement
of treatment. The hormonal assays were carried out on
supernatant fluid maintained between 2 and 8°C. AFCs were
assessed via transvaginal ultrasonography by utilization of
an Aloka SSD‑1000 (Japan) with a 5 MHz probe, on menstrual
cycle day 3. Follicular diameter of <10 mm was used as a
cutoff while counting in both ovaries to determine the cohort
with inter observer coefficient of variation (CV) <5%.
All samples were assayed employing the use of AMH Gen
11 ELISA reagent kit (Beckman coulter, ref a79765) with
an analytical sensitivity of 0.57 pmol/L. Intra‑assay CV
was <5.4% while inter‑assay CV was 5.6%. Regarding FSH,
samples were assayed utilizing the Elecys reagent kit with
intra‑assay CV of <3% and inter‑assay CV of <6%.

RESULTS
In our study, the mean body mass index (BMI) of the
participants was higher than the South Asia cutoff for
obesity, i.e. 25 kg/m2. The mean serum AMH levels were
recorded as 1.6 ± 1.37 ng/ml although the mean age was
observed as 33.6 ± 6.03 year. The serum FSH levels, as well as
AFC of the whole population, was recorded within normal
range as listed in Table 2.
Subsequently, the participants were divided into three
groups based on their evaluation of the number of
antral follicles. Group A comprised individuals with
AFC <5 follicles, Group B had a range from 5 to 19 follicles
while Group C included participant with AFC >19 follicles.
Table 3 presents the biophysical and biochemical variables
of the cohort subgrouped according to the AFC criterion.
The post hoc analysis between AFC and parameters such as
age, BMI, FSH, and AMH highlighted the significance of
these markers in categorizing the three groups.
Age appeared to be a significant predictor for females
having very low number of ovarian follicles (P < 0.01) but
it failed to differentiate between those with normal or more
than 19 follicles (P = 0.65) (Groups B and C).
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Table 2: Descriptive statistics of the whole cohort
Variables
Age (year)
BMI (kg/m2)
FSH (IU/L)
LH (IU/L)
AMH (ng/ml)
AFC
Infertility (year)

Whole study population, n=160 (mean±SD)
33.6±6.03
29.3±5.41
8.5±4.8
6.9±1.06
1.6±1.37
8.8±4.3
7.6±5.6

Data expressed as mean±SD. Mann–Whitney U‑test was used to compare the
difference between groups. *P<0.05 considered significant. BMI=Body mass index;
FSH=Follicular stimulating hormone; LH=Luteinizing hormone; AFC=Antral follicle
count; AMH=Anti Mullerian hormone; SD=Standard deviation

Table 3: Biophysical and biochemical variables on the
basis of antral follicle count cut‑off
Variables
Age (year)
BMI (kg/m2)
FSH (IU/L)
LH (IU/L)
AMH (ng/ml)
AFC

<5 (n=38)
36.6±5.5*
31.9±5.1
10.1±5.6*
7.1±7.6
0.5±0.6*
3.5±0.5

AFC (mean±SD)
5–19 (n=78)
33.2±6.5
28.6±5.7
8.5±5.1
6.3±8.6
1.7±1.3*
7.6±1.2

>19 (n=44)
32±4.6
29.2±4.5
7.25±3.4
8.2±5.7
2.2±1.7*
14.8±4.7

Data expressed as mean±SD. Mann–Whitney U‑test was used to compare the
difference between groups. *P<0.05 considered significant. BMI=Body mass index;
FSH=Follicular stimulating hormone; LH=Luteinizing hormone; AFC=Antral follicle
count; AMH=Anti Mullerian hormone; SD=Standard deviation

The difference in FSH was found to be nonsignificant
among patients in Groups A and B (P = 0.08) and between
Groups B and C (P = 0.84). Moreover, it was merely able to
significantly differentiate between patients with <5 follicles
and those with more than 19 follicles (P = 0.009).
AMH was found to be the most comparable predictor to
AFC in categorizing the population as there was a significant
difference among all three groups. The P value was highly
significant among patients with low AFC and normal
AFC, i.e., Group A and B (P = 0.002) as well as between
Groups A and C (P = 0.001). Furthermore, AMH levels were
successful in highlighting the significant difference between
Group B and C (P = 0.04).
Finally, we performed ordinal regression analysis adjusting
for age and BMI to estimate the odds ratio for determining
the effect of AMH and FSH on AFC variations. The odds
for AMH were 0.14 (95% confidence interval [CI]: 0.03,
0.65 (P < 0.01)), while the odds for FSH was 1.42 (95% CI:
0.72, 2.79 [P = 0.73]). As compared to FSH, AMH gave a
better prediction of variation in the AFC.

DISCUSSION
In human‑assisted reproduction, ovarian response to
gonadotropin stimulation is variable, hence, difficult
to predict. [10] The evaluation of antral follicles on the
3

transvaginal scan is often used as a gold standard to assess
OR, standardize the dose of treatment, and to predict the
likelihood of conception with the help of intervention. In
this study, we compared the effectiveness of FSH; widely
used OR and recently emerged AMH in reflecting the count
of antral follicles in infertile females.
In our study, the mean age of infertile patients was found
to be approximately 33 years. As chronological age is used
as a marker of OR since many years, we scrutinized its
strength in reflecting the follicular pool. Expectedly, higher
age correlated with patients whom AFC had drastically
declined, suggesting deterioration in the ovarian pool as
female ages. However, it failed to segregate between women
with healthy counts of follicles or an overblown AFC that is
critical to reduce undesired effects of treatment. Literature
too recommends age as a week reflector of the reserve as
it is widely reported to differ even among age‑matched
population.[11] Even though age does influence the fecundity
of a female but its utility as a marker of OR can only be
substantiated while synergistically using it along other
biochemical and biophysical markers. [12] Undoubtedly,
baseline OR status has an extensive role in infertility
management. Primarily, it is decisive in suggesting either
to wait for natural conception or to proceed for assisted
reproduction. Furthermore, it assists in the standardization
of doses that may lead to satisfactory response, avoiding the
risk of inadequate reaction resulting in failure to retrieve
a decent number of oocytes. In extreme cases, OR might
predict the chances of inappropriate ovarian stimulation
leading to potentially fatal complication termed as OHSS.[13]
Thus, finest prediction of the ovarian pool is essential for
grander results of ART. To this end, in secondary care
hospital where technical expertise is not available to assess
AFC, serum FSH is commonly used as an OR markers other
than age, LH, inhibin, and ovarian volume.[6]
Regarding mean AFC of our study group, we reported
approximately nine follicles per patient. However, while
segregating the participants into three groups based of
their AFC, 24% reported < 5 antral follicles which indicated
determent in their ovarian pool. Likewise, 27.5% population
was at the risk of hyperresponsiveness as they testified more
than nineteen antral follicles on initial assessment. AFC is
considered as the first test of choice in evaluating infertile
patients as it reflects the baseline capability of ovarian
pool to respond to treatment.[11] This promises for timely
identification of women with shortened reproductive life
span, requiring immediate intervention. Moreover, it leads
to appropriate counseling of expected poor responders and
in setting apart those females who may experience enhanced
responsiveness.[13] Contrary to this, AFC evaluation has
its own limitations. These include the requirement of
latest equipment and skilled personnel, biasness due to
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operator’s variability, incapability to visualize follicles in
female with ovarian cysts or prior surgery, and counting
both healthy and atretic follicles as capable to respond
to treatment.[14] Therefore, we compared the strength of
FSH; mostly commonly used OR in secondary care clinics
and AMH; recently acclaimed as the best solo marker to
reflect ovarian pool, in segregating infertile population. As
blood test has a clear advantage of sample collection and
avoidance of human error, these tests may be easily used in
setups lacking the sophisticated technology to assess AFC.[14]
In this investigation, we found that serum FSH was
incapable of significantly indicating sub‑groups with
varied AFC. Although mean FSH levels in patients with
very low AFC were higher (10.1 IU/L) than the other two
sub‑groups as shown in Table 3, they were still within
the normal range (<11 IU/L). This suggests that FSH may
identify individuals only once considerable the loss of
ovarian function has already occurred. Furthermore, the
only significant difference reported in our study was among
FSH levels of patients with <5 follicles and those with more
than 19 follicles; however, it failed to segregate those with
a high chance of life‑threatening OHSS. There have been
discrepancies in the literature regarding the role of FSH as
an accurate OR. Undoubtedly, it is the most widely used
OR marker, but there is ample evidence to state that FSH
levels begins to derange lately; thus, lone assessment of FSH
or along with chronological age is losing their strength as
timely and true indicators of OR.[15]
Interestingly, we found that serum AMH most accurately
clustered the study cohort on the bases of antral follicular
pool. The patients with low AFC had significantly lower
mean AMH levels in comparison to normal as well as higher
follicle count (P = 0.002 and 0.001, respectively). Perhaps the
most striking finding in our investigation is that AMH was
the only parameter that differentiated between the normal
AFC and higher AFC group (P = 0.044). This raises the
possibility of AMH’s clinical value in identifying patients
with likelihood to develop hyperresponse to ovarian
stimulation on the standard doses of gonadotropins.[16]
Timely, identification of such patients would prevent the
drastic complications of the unfortunate phenomenon
OHSS. It may also have the potential to screen for polycystic
ovarian syndrome as women with this condition are likely
to have higher follicle counts, which is well correlated with
AMH levels as our study has shown.[17] Our study strongly
supports the addition of AMH assessment to evaluate
woman before making decisions pertaining to infertility
intervention.
As ethnic variation has been reported in the levels of
AMH across the various population, this is the first study
that compares the strength of FSH and AMH in reflecting
| 2016 |

the follicle count in Pakistani population. A collection
of retrograde data is one of our study’s limitation;
however, it provides ample evidence to support further
studies highlighting the role of AMH as a robust OR
marker. As ethnicity affects the ovarian pool as well as its
responsiveness to ovarian stimulation, local studies are
required to further strengthen the diagnostic role of AMH
in reflecting a response to treatment in various ovarian
dysfunctions.

CONCLUSION
AMH improves the estimation of baseline OR, required
to predict optimum ovarian response during assisted
reproduction. Compared to female age and FSH alone,
AMH has a superior role in projecting accurate antral follicle
pool, especially in setups where technological expertise to
assess AFC is not available. Incorporation of AMH along
with other biomarkers constitutes a better model for the
prediction of ovarian response. Further prospective studies
are required to ascertain its role in predicting the outcomes
of ART in such patients.
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